摘要:
A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand to induce apoptosis and to treat pathological conditions such as cancer, are further provided.
摘要:
The invention relates to monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.
摘要:
A display device is provided and has an optical member, the optical member including: a host, a plurality of light conversion particles distributed in the host to convert a wavelength of light generated from a light source, and a protective layer surrounding the host and including plastic.
摘要:
Disclosed are an optical member, a display device having the same, and a method of fabricating the same. The optical member includes a receiving part having an empty space therein, a host in the receiving part, a plurality of wavelength conversion particles in the host, a sealing part in the receiving part, and a pre-treatment layer between the sealing part and an inner surface of the receiving part.
摘要:
The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
摘要:
The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization.
摘要:
The present invention relates to a modified thiolase protein with an improved activity, a polynucleotide encoding the modified protein, an expression vector including the polynucleotide, and a transformant, to a composition for producing a biobutanol including the thiolase with an improved activity or a cell expressing the thiolase, and to a method of producing the biobutanol.
摘要:
A mobile terminal including a communication unit configured to provide a communication function including at least one of an outgoing communication function and an incoming communication function, a controller configured to acquire surrounding data including at least one of image data or sound data corresponding to a surrounding of where the communication function is performed, and to match the acquired surrounding data with communication information indicating a first party of the outgoing function or a second party of the incoming communication function, and a display unit configured to display a communication history including the communication information matched with the surrounding data. In addition, the controller is further configured to acquire the surrounding data selectively based on a) a manual operation of the terminal or b) automatically without user intervention.
摘要:
The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
摘要:
The present invention relates to a method for measuring human intelligence using a neurobiogical model. The invention provides a method which enables neurometric IQ to be measured by processing the MRI and fMRI images of subjects to determine cortical thicknesses and brain activation levels, determining structural IQ (sIQ) and functional IQ (fIQ) from the cortical thicknesses and the brain activation levels, and using the structural IQ (sIQ) and the functional IQ (fIQ) as predictors to measure the neurometric IQ of the subject. According to the present invention, the concept of a neurometric IQ (nIQ) model is established and can assist in easily assessing individual differences in general cognitive ability. These results suggest that general cognitive ability can be explained by two different neural bases or traits: facilitation of neural circuits and accumulation of crystallized knowledge.